RT Journal Article
SR Electronic
T1 Joint EANM, SNMMI and IAEA Enabling Guide: How to Set Up a Theranostics Centre
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP jnumed.122.264321
DO 10.2967/jnumed.122.264321
A1 Ken Herrmann
A1 Luca Giovanella
A1 Andrea Santos
A1 Jonathan Gear
A1 Pinar Ozgen Kiratli
A1 Jens Kurth
A1 Ana M. Denis-Bacelar
A1 Roland Hustinx
A1 Marianne Patt
A1 Richard L. Wahl
A1 Diana Paez
A1 Francesco Giammarile
A1 Hossein Jadvar
A1 Neeta Pandit-Taskar
A1 Munir Ghesani
A1 Jolanta Kunikowska
YR 2022
UL http://jnm.snmjournals.org/content/early/2022/04/21/jnumed.122.264321.abstract
AB The theranostics concept using the same target for both imaging and therapy dates back to the middle of the last century, when radioactive iodine was first used to treat thyroid diseases. Since then, radioiodine has become broadly established clinically for diagnostic imaging and therapy of benign and malignant thyroid disease, worldwide. However, only since the approval of SSTR2-targeting theranostics following the NETTER-1 trial in neuroendocrine tumours, and the positive outcome of the VISION trial has theranostics gained substantial attention beyond nuclear medicine. The roll-out of radioligand therapy for treating a high-incidence tumour such as prostate cancer requires the expansion of existing, and the establishment of new theranostics centres. Despite wide global variation in the regulatory, financial and medical landscapes, this guide attempts to provide valuable information to enable interested stakeholders to safely initiate and operate theranostic centres. This enabling guide does not intend to answer all possible questions, but rather to serve as an overarching framework for multiple, more detailed future initiatives. It recognizes that there are regional differences in the specifics of regulation of radiation safety, but common elements of best practice valid globally.